Chinese Drug Maker Thousand Oaks Biopharmaceuticals Nets $44M In Series A Round

Violet Tang
January 2, 2019 — 15:53 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: acquisition Addor Capital biotech China chinese guangdong healthcare investment jiangsu Jilin manufacturing medicine New Alliance Capital pharmaceutical shenzhen technology Thousand Oaks Biopharmaceuticals venture capital

Related News:

Bahrain’s Investcorp Targets RMB2-4 Billion Buyout Fund in China

November 25, 2023 — 00:58

Chinese Generative AI Startups Secure Substantial Funding in Race to Replicate OpenAI’s Success

November 13, 2023 — 23:55

Middle Eastern Sovereign Wealth Funds Deepen Investment in China

November 10, 2023 — 23:35

Kai-Fu Lee’s AI Firm 01.AI Hits Unicorn Status with Alibaba Cloud-Led Funding

November 7, 2023 — 00:55

AI-Driven Pharmaceutical Startups Attract Soaring Investor Interest

November 5, 2023 — 03:24

Tencent Was Involved In 77 Investments Worth $11.9 Billion From 2021 To 2022 YTD; We Have It All In This One List

March 28, 2022 — 23:58

WeRide Closed Series C Round Fundraising From Alliance Ventures, China Structural Reform Fund And Pro Capital

June 23, 2021 — 20:25

Yufeng Capital: Expect To Live To 120 Years As China Realizes Digital Healthcare

April 24, 2021 — 04:25

Chinese IDM Startup InnoStar Semiconductor Secures $100M

April 8, 2021 — 01:15